Other Events ·
SciSparc Ltd.'s subsidiary NeuroThera Labs reported significant enrollment momentum for SCI-210, a cannabinoid-based…
SPRCSciSparc Ltd.
SciSparc Ltd.'s subsidiary NeuroThera Labs reported significant enrollment momentum for SCI-210, a cannabinoid-based treatment for autism spectrum disorder (ASD), with 26 of the planned 60 children enrolled in its double-blind trial at Soroka Medical Center. The company is also pursuing FDA Orphan Drug Designation for SCI-110, a drug candidate for adult Tourette syndrome, and has engaged RK Strategies to support this regulatory effort. SCI-110 is currently in Phase IIb trials across the US, Germany, and Israel, following Phase IIa results showing a 21% average tic reduction. SciSparc Ltd. operates in the pharmaceutical industry, developing cannabinoid-based therapeutics for central nervous system disorders.